Clinical trials: Autoimmune Disorder
Immunoglobulin A Nephropathy, Glomerular Disease
Safety and Efficacy Study of VIS649 for IgA Nephropathy
The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Trial name
- NCT04287985
- Testing
- Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Where
- 93 sites in United States, Australia and 13 more
- Volunteers
- 155 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Multiple Sclerosis
Improving Prospective Memory Via Telehealth
Up to 70% of persons with multiple sclerosis (PwMS) experience cognitive impairment, which can have a significant impact on several aspects of their daily lives.
- Trial name
- TPMI (NCT05129293)
- Testing
- Prospective Memory Intervention, Educational
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Trinity Health Of New England
Rheumatoid Arthritis
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
The purpose of this study is to evaluate the long term safety and tolerability of fostamatinib in patients with rheumatoid arthritis (RA).
- Trial name
- OSKIRA-X (NCT01242514)
- Testing
- Fostamatinib
- Where
- 308 sites in United States, Argentina and 29 more
- Volunteers
- 1,917 people
- Sponsor
- AstraZeneca
Multiple Sclerosis, Fatigue
A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
This study assesses the safety, tolerability, and efficacy of suvorexant in multiple sclerosis patients. Enrolled subjects will receive 2 weeks of treatment during treatment period 1 with either suvorexant or matching placebo…
- Conditions
- Multiple Sclerosis, Fatigue, Insomnia
- Trial name
- DREAM (NCT03110315)
- Testing
- Suvorexant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Theodore R. Brown, MD MPH
Diabetes Mellitus, Type 1
Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days
Placebo-controlled, double blind (triple-dummy technique), randomised parallel design comparison of three oral doses (2.5 mg, 10 mg, and 25 mg) of empagliflozin in patients with T1DM as adjunctive therapy to insulin over 28 days.
- Trial name
- NCT01969747
- Testing
- Empagliflozin medium, Empagliflozin low
- Where
- 2 sites in Austria, Germany
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1
EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes
The objectives of this study is to: Evaluate the tolerability of a combination therapy with Diamyd, vitamin D and etanercept Evaluate how the above mentioned treatments influence the immune system and endogenous insulin secretion
- Trial name
- NCT02464033
- Testing
- GAD-Alum, Vitamin D, Etanercept
- Where
- 8 sites in Sweden
- Volunteers
- 20 people
- Sponsor
- Johnny Ludvigsson
Neuromyelitis Optica
Scrambler Trial for Pain in NMOSD
A novel technology called Scrambler Therapy is a non-invasive pain modifying technique that utilizes transcutaneous electrical stimulation of C fibers with the intent of re-organizing maladaptive signaling pathways.
- Trial name
- NCT03452176
- Testing
- Scrambler
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Johns Hopkins University
Rheumatoid Arthritis
Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management
The aim of the proposed project is to compare the effectiveness of two strategies designed to enhance patient understanding of medication risks/benefits: (1) Medication Guides, mandated for many medications by the Food and Drug…
- Trial name
- NCT02820038
- Testing
- Medication Guides, SMART Program, Drug Facts Boxes
- Where
- United States
- Volunteers
- 286 people
- Sponsor
- University of North Carolina, Chapel Hill
Rheumatoid Arthritis
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
This randomized, multicenter, double-blind, parallel group study will evaluate the impact of MTX discontinuation on the efficacy of SC TCZ in participants with moderate to severe active rheumatoid arthritis who have an inadequate…
- Trial name
- NCT01855789
- Testing
- Tocilizumab (TCZ), Methotrexate (MTX)
- Where
- 155 sites in United States
- Volunteers
- 718 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
Study in participants with RA who have an inadequate response to methotrexate.
- Trial name
- NCT00950989
- Testing
- Brodalumab, Methotrexate, folic acid
- Volunteers
- 252 people
- Sponsor
- Amgen
Lupus Erythematosus, Systemic
A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus
Primary objective: To assess the efficacy and safety of different dose regimens of ALX-0061 administered subcutaneously (s.c.) to subjects with moderate to severe active, seropositive systemic lupus erythematosus (SLE) compared…
- Trial name
- NCT02437890
- Testing
- ALX-0061
- Where
- 118 sites in United States, Argentina and 15 more
- Volunteers
- 312 people
- Sponsor
- Ablynx, a Sanofi company
Type 1 Diabetes Mellitus
Hypoglycemia Prevention After Exercise in Adolescent T1DM Patients Using a Control to Range System
In this protocol the investigators plan to demonstrate management of glucose using a modular insulin management system based on continuous glucose monitoring and targeted towards the avoidance of hypoglycemic and prolonged…
- Trial name
- MDB005 (NCT01390259)
- Testing
- Open-Loop, Closed-Loop
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Virginia
Immunosuppresion, Thrombocytopenia
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular bone marrow.
- Conditions
- Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
- Trial name
- NCT00260689
- Testing
- Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Rheumatoid Arthritis
A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.
This single arm study will assess the effectiveness of tocilizumab in combination with traditional DMARDs with regard to the clinical improvement in disease activity (achievement of LDAS) after 24 weeks' treatment in patients…
- Trial name
- NCT00754559
- Testing
- Tocilizumab
- Where
- 81 sites in Germany
- Volunteers
- 286 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease, Multiple Sclerosis
Expiratory Muscle Training for Persons With Neurodegenerative Disease
Respiratory difficulty is one of the primary factors leading to death in patients with Parkinson's Disease (PD) and Multiple Sclerosis.
- Trial name
- EMST (NCT00856518)
- Testing
- EMST
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- VA Office of Research and Development
Moderate-to-severe Rheumatoid Arthritis
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
The purpose of this study is to evaluate the clinical effectiveness and safety of adalimumab as used in routine clinical practice in adult participants with moderate to severe rheumatoid arthritis (RA) in Canada.
- Trial name
- REACH (NCT01117480)
- Volunteers
- 1,013 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Multiple Sclerosis
Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks
This study will evaluate if patients who had a serious cardiovascular event upon initiation of fingolimod are at risk to delevop long term other cardiovascular events
- Trial name
- NCT02232061
- Testing
- Fingolimod
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 6 people
- Sponsor
- Novartis Pharmaceuticals
Epilepsy, Cryptogenic, Epilepsy, Partial
IVIG Treatment for Refractory Immune-Related Adult Epilepsy
The purpose of the initial screening study is to find out if immune problems are an unrecognized cause of epilepsy in some patients.
- Conditions
- Epilepsy, Cryptogenic, Epilepsy, Partial, Seizure Disorder, Autoimmune Diseases, Nervous System
- Trial name
- NCT01545518
- Testing
- IVIG
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Sjogren's Syndrome
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).
- Trial name
- NCT03100942
- Testing
- Lanraplenib, Filgotinib, Tirabrutinib
- Where
- 53 sites in United States, Poland and 2 more
- Volunteers
- 152 people
- Sponsor
- Gilead Sciences
Aplastic Anemia
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia
Severe aplastic anemia, characterized by pancytopenia and a hypocellular bone marrow, is effectively treated by immunosuppressive therapy, usually a combination of antithymocyte globulin (ATG) and cyclosporine (CsA).
- Trial name
- NCT00065260
- Testing
- Campath-1H, r-ATG, CsA
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.